1. Scrip
  2. >>New Products

This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma

 
• By Eleanor Malone

Janssen Biotech has won FDA approval for Genmab-licensed Darzalex in newly diagnosed multiple myeloma. However, the drug was approved in a combination that is not commonly used in the US. A further label expansion will provide a bigger boost to the anti-CD38 antibody's commercial prospects.

SC1805_Night Sky_277897508_1200.jpg
Clinical Constellation: MAIA combo more relevant to US than ALCYONE trial • Source: Shutterstock

Following a priority review, Johnson & Johnson's Janssen Biotech Inc. has gained supplemental approval in the US for Darzalex (daratumumab) to treat newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant. However, the approval was for a combination of Darzalex with a three-drug regimen known as VMP that is used more commonly in Europe and Japan than the US.

VMP is Velcade (bortezomib), marketed by Takeda Pharmaceutical Co. Ltd. exclusively in the US and partnered in Europe and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 
• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.